Teleflex Incorporated (NYSE:TFX) Receives Average Rating of "Hold" from Analysts

Key Points

• Teleflex Incorporated has received a consensus rating of "Hold" from analysts, with one sell rating, eight hold ratings, and one buy rating.
• The stock price has dropped by 5.1% recently, and analysts set an average price target of $141.57 for the company's shares.
• Incorporating recent earnings results, Teleflex reported $3.73 EPS for the quarter, surpassing expectations, and projected a FY 2025 EPS guidance of $13.90 - $14.30.

Shares of Teleflex Incorporated (NYSE:TFX - Get Free Report) have earned a consensus recommendation of "Hold" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $141.5714.

TFX has been the subject of several recent research reports. Wells Fargo & Company reduced their price objective on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. Wall Street Zen downgraded shares of Teleflex from a "strong-buy" rating to a "buy" rating in a research report on Monday, September 15th. Royal Bank Of Canada increased their price objective on shares of Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a research note on Friday, August 1st. Finally, Mizuho increased their price target on Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a research report on Friday, August 1st.

Teleflex Stock Down 5.1%

Shares of Teleflex stock opened at $117.06 on Friday. Teleflex has a 1 year low of $108.90 and a 1 year high of $249.90. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. The company has a market capitalization of $5.17 billion, a P/E ratio of 27.54, a price-to-earnings-growth ratio of 1.72 and a beta of 1.08. The business has a 50-day moving average of $122.24 and a two-hundred day moving average of $125.38.

Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The business had revenue of $780.90 million during the quarter, compared to analysts' expectations of $771.53 million. During the same period in the prior year, the business earned $3.42 EPS. Teleflex's revenue for the quarter was up 4.2% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. As a group, equities analysts predict that Teleflex will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 15th. Investors of record on Friday, August 15th were paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 1.2%. The ex-dividend date was Friday, August 15th. Teleflex's dividend payout ratio (DPR) is 32.00%.

Insider Buying and Selling

In related news, Director Gretchen R. Haggerty purchased 500 shares of the stock in a transaction on Wednesday, August 6th. The shares were purchased at an average cost of $114.75 per share, with a total value of $57,375.00. Following the acquisition, the director directly owned 6,305 shares in the company, valued at $723,498.75. The trade was a 8.61% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Liam Kelly bought 1,500 shares of the stock in a transaction dated Tuesday, August 5th. The shares were purchased at an average price of $115.07 per share, for a total transaction of $172,605.00. Following the purchase, the chief executive officer owned 45,267 shares of the company's stock, valued at $5,208,873.69. This trade represents a 3.43% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 5,500 shares of company stock valued at $633,590. Insiders own 1.40% of the company's stock.

Hedge Funds Weigh In On Teleflex

A number of hedge funds have recently bought and sold shares of TFX. T. Rowe Price Investment Management Inc. grew its position in shares of Teleflex by 0.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 6,216,763 shares of the medical technology company's stock worth $859,095,000 after purchasing an additional 43,642 shares in the last quarter. Cooke & Bieler LP raised its holdings in Teleflex by 14.0% in the 2nd quarter. Cooke & Bieler LP now owns 1,205,964 shares of the medical technology company's stock valued at $142,738,000 after acquiring an additional 148,436 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Teleflex by 69.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company's stock valued at $119,927,000 after acquiring an additional 355,720 shares during the period. Qube Research & Technologies Ltd grew its holdings in shares of Teleflex by 100.1% during the 2nd quarter. Qube Research & Technologies Ltd now owns 606,804 shares of the medical technology company's stock worth $71,821,000 after purchasing an additional 303,521 shares in the last quarter. Finally, Diamond Hill Capital Management Inc. increased its position in shares of Teleflex by 122.8% in the first quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company's stock worth $80,784,000 after purchasing an additional 322,222 shares during the period. 95.62% of the stock is owned by institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.